- Home
- RDHL vs GRI Comparison
RDHL vs GRI Comparison
Compare RDHL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- GRI
- Stock Information
- Founded
- RDHL 2009
- GRI 2018
- Country
- RDHL Israel
- GRI United States
- Employees
- RDHL N/A
- GRI N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- GRI Health Care
- Exchange
- RDHL Nasdaq
- GRI Nasdaq
- Market Cap
- RDHL 3.8M
- GRI 3.2M
- IPO Year
- RDHL N/A
- GRI N/A
- Fundamental
- Price
- RDHL $1.85
- GRI $1.26
- Analyst Decision
- RDHL
- GRI Strong Buy
- Analyst Count
- RDHL 0
- GRI 2
- Target Price
- RDHL N/A
- GRI $22.00
- AVG Volume (30 Days)
- RDHL 18.5K
- GRI 112.3K
- Earning Date
- RDHL 04-10-2025
- GRI 08-13-2025
- Dividend Yield
- RDHL N/A
- GRI N/A
- EPS Growth
- RDHL N/A
- GRI N/A
- EPS
- RDHL N/A
- GRI N/A
- Revenue
- RDHL $8,042,999.00
- GRI N/A
- Revenue This Year
- RDHL $381.91
- GRI N/A
- Revenue Next Year
- RDHL N/A
- GRI N/A
- P/E Ratio
- RDHL N/A
- GRI N/A
- Revenue Growth
- RDHL 23.17
- GRI N/A
- 52 Week Low
- RDHL $1.71
- GRI $1.10
- 52 Week High
- RDHL $20.28
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- RDHL 43.03
- GRI 40.16
- Support Level
- RDHL $1.72
- GRI $1.28
- Resistance Level
- RDHL $2.08
- GRI $1.45
- Average True Range (ATR)
- RDHL 0.09
- GRI 0.11
- MACD
- RDHL 0.01
- GRI 0.03
- Stochastic Oscillator
- RDHL 27.78
- GRI 29.30
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.